Food noise reduction is one of GLP-1's most powerful — and least tracked — effects. Appetite changes across your injection cycle, evolves with each dose, and varies person to person. tr8ck maps your hunger and food noise patterns so you understand exactly how your medication is changing your relationship with food.
Food noise is not hunger. It's the constant mental chatter about food — planning the next meal while eating the current one, thinking about food in meetings, feeling controlled by cravings, and never quite switching off the internal conversation about eating.
Thinking about food constantly throughout the day. Planning what to eat next while still eating the current meal. Strong cravings that feel physically urgent. Eating past fullness because stopping feels difficult. Feeling like food occupies disproportionate mental real estate. Many users with this experience feel shame about it — not realising it has a biological basis, not a character flaw.
The most common description from GLP-1 users is simple: "the noise stopped." Food thoughts don't intrude constantly. Meals are finished and then not thought about again. Cravings become easier to dismiss or simply don't arise. Eating becomes less emotionally loaded. Many users describe this as the most significant quality-of-life change from the medication — more impactful than the weight loss itself.
GLP-1 receptors exist throughout the brain, including the nucleus accumbens (reward center) and hypothalamus (appetite regulation). Semaglutide and tirzepatide reduce dopamine-driven food reward signaling — the same mechanism that drives "wanting" food even when not hungry. This is a direct neurobiological effect, not a side effect of being less hungry. Tracking food noise separately from physical hunger captures this important distinction.
Appetite suppression is not uniform across the week. Understanding — and tracking — how it ebbs and flows with your injection cycle prevents both undereating and unexpected hunger spikes.
| Injection cycle day | Typical physical hunger | Typical food noise | What to watch |
|---|---|---|---|
| Day 1 — Injection | Normal to slightly reduced | Often already quiet | Log baseline before effects build |
| Days 2–4 — Peak SE | Very low — nausea suppresses further | Very quiet — but nausea may confuse | Risk of significant undereating — track protein |
| Days 5–6 — Sweet spot | Low to moderate | Quietest food noise window | Best days to focus on protein targets |
| Day 7 — Pre-injection | Moderate — may increase | May return for some users | Track "wear-off" hunger and food noise |
This is a general pattern. Individuals vary significantly. After 3–4 injection cycles of daily logging, your personal pattern will be clear — and often quite different from the population average.
Most GLP-1 users are focused on eating less. The more dangerous problem for long-term outcomes is eating too little — specifically too little protein.
Research shows 25–40% of weight lost on GLP-1 therapy can come from lean mass without deliberate protein tracking. Tracking hunger alongside protein intake catches the days when appetite suppression is so strong that you're simply not getting enough protein — even when the scale is moving in the right direction.
Sustained very low calorie intake (below 1000–1200 kcal for most people) triggers metabolic adaptation. The body downregulates thyroid function and energy expenditure. This creates the paradox of eating very little and losing weight slowly — or plateauing. Tracking hunger plus intake prevents this trap.
Undereating on GLP-1 produces fatigue that many users attribute to the medication itself. Tracking hunger, energy, and nutrition together reveals when fatigue is caused by undereating rather than the drug — a distinction that changes the solution completely.
Rather than tracking total calories on GLP-1, focus on hitting a daily protein target: 0.7–1g per pound of goal body weight. When protein is hit and you're in a genuine caloric deficit, weight loss is both faster and higher quality (more fat, less muscle). Appetite tracking flags the days when protein intake is at risk.
A simple daily log that takes under 2 minutes generates powerful data over 4–8 weeks.
Rate physical hunger once in the morning and once before your main meal. 1 = no hunger at all, 5 = very hungry. This tracks whether appetite suppression is working throughout your injection cycle and how it changes with dose escalation.
Separate from physical hunger: how much mental space is food occupying today? 1 = completely quiet, 5 = constantly thinking about food. This is the brain-level effect of GLP-1 that hunger ratings don't capture — and tracking it separately reveals the medication's neurological impact week over week.
Log your approximate meal size (small / medium / normal) and whether you snacked. Over weeks, this shows how GLP-1 is changing your eating patterns at the behavioural level — smaller portions, fewer snacks, less grazing between meals.
Log daily protein intake. This is most important on your lowest-hunger days (typically days 2–4 post-injection) when the risk of protein deficit is highest. Your protein log, combined with hunger ratings, immediately shows you which days need deliberate effort to hit your target.
Hunger on GLP-1 connects to sleep (poor sleep raises ghrelin), mood (food noise has emotional dimensions), nutrition (what and how much you ate), and energy (low intake causes fatigue). tr8ck tracks every connection.
Food noise is the constant mental preoccupation with food — intrusive thoughts about eating, persistent cravings, and a feeling of being controlled by food rather than in control of it. GLP-1 receptor agonists act on brain reward centers and significantly reduce this for most users, often within the first few weeks. Many users describe food noise reduction as more life-changing than the weight loss itself.
Rate physical hunger (1–5) daily, rate food noise intensity separately (1–5), note meal sizes and snacking frequency, and log protein intake. Consistent daily logging for 3–4 injection cycles reveals your personal appetite pattern — which days are lowest, whether food noise is genuinely diminishing over time, and when you're at risk of undereating.
For many semaglutide users, yes — appetite and food noise begin returning on day 6–7. This "wear-off" effect is more common with Ozempic and Wegovy than with tirzepatide (Mounjaro/Zepbound). If you're consistently experiencing significant hunger and food noise return on day 7, track it carefully and discuss with your prescriber — it may indicate a dose or timing adjustment is warranted.
Tracking hunger prevents undereating — particularly protein undereating — which causes muscle loss and metabolic slowdown that undermines long-term results. It also reveals whether the medication is providing adequate appetite control across your full weekly cycle, informing prescriber conversations about dose and timing. And it documents the food noise reduction that many users find most valuable but rarely think to track.
Signs of adequate suppression: smaller portions feel satisfying, you can stop eating when full, food noise has meaningfully reduced, and you're not thinking about food constantly between meals. Signs of insufficient suppression: persistent hunger between meals, unchanged food noise, and eating similar amounts as before. Daily hunger ratings tracked over 4+ weeks confirm objectively which category you're in — and whether it's improving with dose escalation.
Free during early access. All 13 modules. Works for Ozempic, Wegovy, Mounjaro, and Zepbound. No credit card required.
Try tr8ck FreeAlso worth reading